Tradestie Institutional Equity Comparison Engine

ENTA vs CGEM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEM Overall Edge

CGEM Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ENTA trades at 44.0x Forward P/E with -90.0% operating margin (-21.6% YoY revenue) versus CGEM at 6.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTA sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro) against CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEM
ENTA 44.0x vs CGEM 6.7x Fwd P/E
Growth & Margin Winner CGEM
Op Margin -90.0% vs 0.0% ยท YoY -21.6% vs +0.0%
Momentum & Technical Winner CGEM
1Y -7.9% vs +16.7% ยท 52W Pos 10% vs 11%
Options & Structure Winner CGEM
BREAKDOWN (11th %ile IV) vs UNCLASSIFIED (9th %ile IV)
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
1M Return -2.79%
1Y Return -7.94%
Forward P/E 44.0x
Unified AI Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.65
-6.13% 1D
Market Cap $653.8M
1M Return -25.37%
1Y Return +16.69%
Forward P/E 6.7x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTA -7.94% CGEM +16.69% Spread: +24.63 pp (CGEM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ENTA TTM Op. Margin: -90.0% CGEM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTA vs CGEM. Trailing 12-month operating profitability (ENTA -90.0% vs CGEM 0.0%) and valuation multiples (ENTA 44.0x vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTA (2) vs CGEM (8)
Institutional Metric ENTA CGEM Criterion Row Winner
Market Capitalization Scale $326.2M $653.8M Larger Scale CGEM
Trailing P/E Ratio Valuation 44.0x 6.7x Lower Multiple CGEM
Forward P/E Ratio Valuation 44.0x 6.7x Lower Multiple CGEM
Revenue Growth (YoY) Growth -21.6% +0.0% Higher Growth CGEM
Operating Margin (TTM) Profitability -90.0% 0.0% Higher Margin CGEM
Net Profit Margin Profitability -96.9% 0.0% Higher Margin CGEM
Return on Equity (ROE) Capital Efficiency -70.1% -50.3% Higher ROE CGEM
52-Week Range Position Momentum 10% ($10โ€“$17) 11% ($8โ€“$23) Stronger Trend CGEM
Beta / 30D Volatility Risk Regime 0.89ฮฒ ยท 58% Vol 1.58ฮฒ ยท 105% Vol Lower Realized Risk ENTA
Unified Institutional Score Composite Signal 46.2 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite ENTA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTA vs CGEM Buy Guide
ENTA BREAKDOWN
95d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live ENTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live CGEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTA nor CGEM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.